Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2023 / Feb / A Bank of Biomarkers
Neurology Neurology Genetics and epigenetics Screening and monitoring Omics

A Bank of Biomarkers

Investigating biomarkers for early dementia diagnosis

By Georgia Hulme 02/08/2023 News 1 min read

Share

The onset of Alzheimer’s disease (AD) – the most common form of dementia – is an anxiety-inducing possibility for everyone as they reach old age. Clinical trials have so far failed to develop novel therapeutics for the disease and diagnosis remains challenging, particularly in the early stages. However, one thing is certain: biomarkers are a beacon of hope for early detection and to allow researchers to track dementia progression.


Tau proteins, commonly found in the neurons, are well-known biomarkers of AD. Post-translational modifications often lead to an accumulation of abnormal tau proteins. In a recent study, researchers from North Carolina, US, tested several tau antibodies using post-mortem brain tissue from AD patients and non-AD subjects (1). The antibody screening revealed several tau phosphorylation sites, including p-tau198, that occur at high frequencies in the brains of AD patients. As proof of principle, the researchers showed that p-tau198 can differentiate between AD and non-AD brains, meaning it could be a suitable biomarker for AD detection as a patient transitions into mild cognitive impairment. p-tau198 is also more sensitive and specific than existing AD biomarkers p-tau181 and p-tau217.

Another biomarker breakthrough identified circulating cell-free genomic DNA (ccf-DNA) as a possible indicator that an individual might have a higher risk of developing dementia and a decline in physical function (2). Over eight years, researchers collected blood-based serum from 631 individuals without cognitive impairment. Quantification of ccf-DNA fragments using digital PCR confirmed that higher ccf-DNA levels were correlated with increased odds of incident dementia, steeper general cognitive decline, and frailty.

Image Credit : StarGladeVintage / Pixaby.com

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. L Wu et al., ACS Chem Neurosci, 13, 3281 (2022). PMID: 36350059.
  2. LS Nidadavolu et al., J Alzheimers Dis, 89, 1233 (2022). PMID: 36031893.

About the Author(s)

Georgia Hulme

Associate Editor for the Pathologist

More Articles by Georgia Hulme

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

The Shapeshifting Cancer
Neurology
The Shapeshifting Cancer

February 24, 2022

1 min read

Understanding the heterogeneity and plasticity of glioblastoma

Image of the Month
Neurology
Image of the Month

October 21, 2016

1 min read

Who Will Be The Caretakers?
Neurology
Who Will Be The Caretakers?

August 4, 2022

3 min read

Recent allegations of image manipulation in a major Alzheimer’s disease paper reaffirm the importance of research integrity

Getting to the Genetic Core of Autism
Neurology
Getting to the Genetic Core of Autism

August 15, 2022

2 min read

Investigating the genotype-phenotype relationship in autism to improve our understanding of heterogeneity

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.